Literature DB >> 8013881

A simple and reliable method of producing in vitro infections of Cryptosporidium parvum (Apicomplexa).

S J Upton1, M Tilley, M V Nesterenko, D B Brillhart.   

Abstract

A variety of techniques have been used to infect cell monolayers in culture with the protozoan, Cryptosporidium parvum. However, most of these methods rely on the use of trypsin and/or bile salts to excyst sporozoites in vitro, followed by washing sporozoites free of excystation solution prior to their addition to subconfluent monolayers. This method not only increases the amount of time required to establish infections in vitro, but also results in prolonged exposure of free sporozoites to environmental conditions. Here we report a simple, fast, and efficient method of obtaining consistent infections of C. parvum in cell monolayers. This technique relies on the ability of the parasite to excyst at 37 degrees C but not at room temperature following pretreatment with sodium hypochlorite. By adding surface-sterilized oocysts directly to monolayers, sporozoites have access to host cells immediately upon excystation.

Entities:  

Mesh:

Year:  1994        PMID: 8013881     DOI: 10.1111/j.1574-6968.1994.tb06801.x

Source DB:  PubMed          Journal:  FEMS Microbiol Lett        ISSN: 0378-1097            Impact factor:   2.742


  22 in total

1.  Short-term exposure to membrane-active antibiotics inhibits Cryptosporidium parvum infection in cell culture.

Authors:  A Giacometti; O Cirioni; M S Del Prete; F Barchiesi; G Scalise
Journal:  Antimicrob Agents Chemother       Date:  2000-12       Impact factor: 5.191

2.  Decrease in Cryptosporidium parvum oocyst infectivity in vitro by using the membrane filter dissolution method for recovering oocysts from water samples.

Authors:  R A Carreno; N J Pokorny; S C Weir; H Lee; J T Trevors
Journal:  Appl Environ Microbiol       Date:  2001-07       Impact factor: 4.792

Review 3.  In vitro cultivation of cryptosporidium species.

Authors:  Michael J Arrowood
Journal:  Clin Microbiol Rev       Date:  2002-07       Impact factor: 26.132

4.  CpABC, a Cryptosporidium parvum ATP-binding cassette protein at the host-parasite boundary in intracellular stages.

Authors:  M E Perkins; Y A Riojas; T W Wu; S M Le Blancq
Journal:  Proc Natl Acad Sci U S A       Date:  1999-05-11       Impact factor: 11.205

5.  [(1)N,(12)N]Bis(Ethyl)-cis-6,7-dehydrospermine: a new drug for treatment and prevention of Cryptosporidium parvum infection of mice deficient in T-cell receptor alpha.

Authors:  W R Waters; B Frydman; L J Marton; A Valasinas; V K Reddy; J A Harp; M J Wannemuehler; N Yarlett
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

Review 6.  Susceptibility Testing of Medically Important Parasites.

Authors:  Abebe Genetu Bayih; Anjan Debnath; Edward Mitre; Christopher D Huston; Benoît Laleu; Didier Leroy; Benjamin Blasco; Brice Campo; Timothy N C Wells; Paul A Willis; Peter Sjö; Wesley C Van Voorhis; Dylan R Pillai
Journal:  Clin Microbiol Rev       Date:  2017-07       Impact factor: 26.132

7.  Generating and Maintaining Transgenic Cryptosporidium parvum Parasites.

Authors:  Mattie C Pawlowic; Sumiti Vinayak; Adam Sateriale; Carrie F Brooks; Boris Striepen
Journal:  Curr Protoc Microbiol       Date:  2017-08-11

8.  Development of a novel, rapid integrated Cryptosporidium parvum detection assay.

Authors:  D Kozwich; K A Johansen; K Landau; C A Roehl; S Woronoff; P A Roehl
Journal:  Appl Environ Microbiol       Date:  2000-07       Impact factor: 4.792

9.  An in vitro method for detecting infectious Cryptosporidium oocysts with cell culture.

Authors:  T R Slifko; D Friedman; J B Rose; W Jakubowski
Journal:  Appl Environ Microbiol       Date:  1997-09       Impact factor: 4.792

10.  Comparison of method 1623 and cell culture-PCR for detection of Cryptosporidium spp. in source waters.

Authors:  Mark W LeChevallier; George D Di Giovanni; Jennifer L Clancy; Zia Bukhari; Shan Bukhari; Jeffrey S Rosen; Jose Sobrinho; Michelle M Frey
Journal:  Appl Environ Microbiol       Date:  2003-02       Impact factor: 4.792

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.